OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Organization: Stanford University

5 Projects | 4 Researchers | $1,251,917 Invested

2025

Stanford University

Michelle James, PhD

Development of new PET radiotracers for detecting and tracking innate immune activation in the whole body and CNS of Alzheimer's disease

  • Funding Amount: $350,385
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Active

2025

Stanford University

Giuseppe Barisano, MD, PhD

Assessing the diagnostic and prognostic value of perivascular spaces imaging in cognitive impairment and dementia through a novel fully-automated robust algorithm

  • Funding Amount: $128,500
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Active

2020

Stanford University

Thomas Montine, MD, PhD

Blood-based immune biomarkers for Alzheimer's disease diagnosis and its early detection

  • Funding Amount: $468,500
  • Organization Type: Academic/Nonprofit
  • Program: Diagnostics Accelerator
  • Target: Systemic Inflammation
  • Status: Closed

2005

Stanford University

Tony Wyss-Coray, PhD

The TGF-Beta Pathway as a Therapeutic Target to Treat Alzheimer’s Disease

  • Funding Amount: $152,300
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2003

Stanford University

Tony Wyss-Coray, PhD

The TGF-Beta Pathway as a Therapeutic Target to Treat Alzheimer's Disease

  • Funding Amount: $152,232
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed